Cell/Gene Tx channel feed

A gene edit­ing 3.0 play­er goes deep on cash, fron­tier sci­ence to put pre­ci­sion epi­ge­net­ics to the big test

3 years ago
Financing
Bioregnum

Re­gen­er­a­tive cell biotech Thym­mune launch­es with back­ing from George Church, John Maraganore

3 years ago
Financing

Gene ther­a­py start­up Lo­can­abio lays off staff, nar­rows fo­cus on Duchenne

3 years ago
People
Startups

Sick­le cell R&D hit by three culls in one day at No­var­tis/In­tel­lia, Sang­amo and Graphite Bio

3 years ago
R&D

Fol­low­ing clin­i­cal hold lift, Astel­las posts ear­ly Pompe gene ther­a­py da­ta

3 years ago
R&D

Myeloid Ther­a­peu­tics goes down un­der for new man­u­fac­tur­ing site, with $66M lo­cal in­vest­ment

3 years ago
Pharma
Manufacturing

Putting a twist on tar­get­ed ther­a­py, Vor Bio­phar­ma her­alds proof of con­cept for its gene-edit­ed stem cells

3 years ago
R&D

CAR-T biotech re­duces staff as it hunts for cap­i­tal to en­ter clin­ic next year

3 years ago
People
Startups

'Rare out­lier­s': Feng Zhang eyes a new path to ge­net­ic med­i­cine de­liv­ery with ex-Al­ny­lam lead­ers and $193M

3 years ago
Financing
Startups

Thou­sands of gene and cell ther­a­pies are in­un­dat­ing FDA re­view­ers as the agency tries to keep up

3 years ago
Pharma
FDA+

AlloVir un­wraps PhII da­ta of cell ther­a­py in ex­pand­ed trans­plant in­di­ca­tion, leaves tri­al plans up in the air

3 years ago
R&D

Re­play part­ners with MD An­der­son’s Katy Rez­vani, heads to clin­ic with new TCR NK cell com­pa­ny

3 years ago
Financing
Startups

Blood stem cell ther­a­py mak­er Garu­da nabs $62M

3 years ago
Financing
Startups

FDA places hold on 4D Mol­e­c­u­lar’s Fab­ry gene ther­a­py

3 years ago
FDA+

BioN­Tech opens new plas­mid DNA man­u­fac­tur­ing fa­cil­i­ty in Ger­many

3 years ago
Pharma
Manufacturing

Man­u­fac­tur­ing roundup: Catal­ent caps off man­u­fac­tur­ing site in Bel­gium; Eu­roAPI restarts pro­duc­tion in Hun­gary

3 years ago
Manufacturing

'Moon­shot' at liv­er cell ther­a­py biotech Am­bys Med­i­cines comes to an end

3 years ago
People
Startups

Four years in, Sana gets first FDA go-ahead to bring can­cer treat­ment in­to the clin­ic

3 years ago
FDA+

J&J, Leg­end say Carvyk­ti beat stan­dard ther­a­py in ear­li­er-line blood can­cer

3 years ago
R&D
Pharma

Xy­lo­Cor wraps up PhII for heart dis­ease gene ther­a­py, plans for piv­otal tri­al

3 years ago
R&D

A stem cell pi­o­neer sent an ex­per­i­ment in­to space. Pa­tients are the next fron­tier

3 years ago
People
In Focus

Can­cer cell-based ther­a­pies com­ing in­to 'im­por­tan­t' year for R&D, say SVB an­a­lysts

3 years ago
Pharma

FDA lifts clin­i­cal hold on Astel­las’ Pompe gene ther­a­py

3 years ago
FDA+

Off Ed­i­tas’ shelves, iNK cell ther­a­pies float to Shore­line

3 years ago
Startups
Deals
First page Previous page 21222324252627 Next page Last page
A service from the Financial Times